Cafergot is a prescription-only migraine medicine that combines ergotamine tartrate and caffeine to stop an attack once it begins. It constricts dilated cranial blood vessels and moderates the inflammatory neuropeptides involved in migraine pain, making it useful for select adults with predictable, severe attacks. It is not a preventive drug and should not be taken daily. Because it can narrow blood vessels beyond the brain, careful dosing, cardiovascular screening, and awareness of drug interactions are essential. Availability can vary by region, and generic ergotamine-caffeine products may be substituted. Always use Cafergot under medical supervision to minimize risks and maximize benefit.
Cafergot is an acute migraine treatment—intended to stop an attack that has already started. Its two active components work together: ergotamine tartrate constricts dilated intracranial blood vessels and inhibits the release of inflammatory neuropeptides, while caffeine enhances ergotamine absorption and adds mild vasoconstrictive and analgesic-sparing effects. This combination can reduce pulsating head pain, photophobia, phonophobia, and nausea in appropriately selected patients.
Cafergot is typically used for migraine with or without aura and, in some cases, for cluster headaches under specialist guidance. It is not a daily preventive (prophylactic) medication and should not be used to reduce the frequency of attacks. Instead, it is taken at the earliest warning signs—often during aura or mild pain—to maximize efficacy and minimize the total amount needed.
Because ergot derivatives can constrict blood vessels throughout the body, Cafergot is not suitable for everyone. It is reserved for adults without significant cardiovascular disease or uncontrolled hypertension, and for those who do not respond well to, or cannot take, other first-line acute migraine therapies like triptans or NSAIDs. Using Cafergot more than the recommended limits increases the risk of medication-overuse headache and rare but serious ischemic complications.
Follow your prescriber’s instructions exactly. A commonly used regimen for Cafergot tablets (ergotamine tartrate 1 mg/caffeine 100 mg) is: take 1–2 tablets at the first sign of a migraine. If needed, 1 additional tablet may be taken every 30 minutes until relief, not to exceed 6 tablets per attack and no more than 10 tablets in any 7-day period. Do not use Cafergot for more than 2 days per week on a regular basis to avoid medication-overuse headaches.
Swallow tablets with water. Taking Cafergot at onset increases the chance of aborting the attack. If nausea is prominent, your clinician may recommend an antiemetic 10–15 minutes beforehand to improve tolerance and absorption. Avoid grapefruit products, which can raise ergotamine levels via CYP3A4 inhibition and increase the risk of toxicity.
Never take Cafergot within 24 hours of a triptan (such as sumatriptan, rizatriptan, zolmitriptan) or another ergot-containing medicine. Likewise, do not take a triptan within 24 hours of Cafergot. Combining vasoconstrictors can provoke dangerous blood vessel spasm and ischemia. If your symptoms are not improving despite the maximum recommended dose, seek medical advice rather than taking more.
Before starting Cafergot, your clinician should evaluate cardiovascular risk factors such as age, smoking status, blood pressure, lipid profile, family history of early heart disease, and any history of Raynaud’s phenomenon or peripheral vascular disease. In higher-risk individuals, additional cardiac evaluation may be recommended before prescribing a vasoconstrictive agent.
Use Cafergot strictly within the prescribed limits. Overuse may lead to medication-overuse headache (rebound), diminishing benefit and amplifying side effects. Smoking or using nicotine products increases the risk of peripheral vasoconstriction and should be avoided. Caffeine in Cafergot can contribute to jitteriness, palpitations, or insomnia; account for all dietary caffeine to reduce overstimulation.
Pregnancy, attempting conception, or breastfeeding require special caution. Ergotamine is contraindicated during pregnancy and postpartum because it can reduce uterine blood flow and milk production. Discuss all medications and supplements you take, especially those affecting liver enzymes (CYP3A4), with your healthcare professional to minimize interaction risks. If you develop chest pain, severe limb pain, coldness or color change in fingers or toes, new numbness/weakness, or severe abdominal pain after taking Cafergot, seek urgent care.
Do not use Cafergot if you have: coronary artery disease, history of myocardial infarction, stroke or TIA, peripheral vascular disease, uncontrolled hypertension, severe hepatic or renal impairment, sepsis, or known hypersensitivity to ergot alkaloids. It is also contraindicated in pregnancy and during breastfeeding, and should not be used for hemiplegic or basilar-type migraine.
Avoid Cafergot if you are taking potent CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, ketoconazole, itraconazole, voriconazole, cobicistat, ritonavir, nelfinavir, indinavir) because these can dramatically increase ergotamine blood levels and precipitate life-threatening vasospasm and ischemia. Do not take Cafergot within 24 hours of a triptan or any other ergot-containing medication.
Common side effects include nausea, vomiting, abdominal discomfort, flushing, dizziness, and fatigue. Because the caffeine component can be stimulating, some people experience jitteriness, tremor, palpitations, anxiety, or insomnia, especially if other caffeine sources are consumed.
Vasoconstrictive effects may cause tingling, numbness, coldness, or pain in fingers and toes; muscle cramps; and, rarely, chest pressure. If you notice blue or pale discoloration of extremities, severe limb pain, reduced pulses, or chest pain, stop the medication and seek immediate medical care—these can be signs of significant ischemia (ergotism).
Less commonly, ergotamine has been associated with fibrosis (e.g., pleural, retroperitoneal) after prolonged, excessive use. This is one reason Cafergot should only be used intermittently and within limits. Any new shortness of breath, persistent cough, back or abdominal pain, or urinary changes after chronic ergot exposure warrants prompt evaluation.
Serious interactions occur with strong CYP3A4 inhibitors, which can cause dangerously high ergotamine levels. Avoid combining Cafergot with macrolide antibiotics (clarithromycin, erythromycin, telithromycin), azole antifungals (ketoconazole, itraconazole, voriconazole, posaconazole), HIV protease inhibitors (ritonavir, nelfinavir, indinavir), cobicistat-boosted regimens, and grapefruit or Seville orange products. Always inform your clinician and pharmacist about all prescriptions, OTC medicines, and supplements.
Do not use Cafergot within 24 hours of any triptan (sumatriptan, rizatriptan, zolmitriptan, eletriptan, almotriptan, frovatriptan, naratriptan) or other ergot derivatives (dihydroergotamine, methylergonovine) because additive vasoconstriction can cause ischemia. Combining Cafergot with nicotine, vasoconstrictive decongestants (e.g., pseudoephedrine), or certain beta-blockers may increase peripheral vasospasm risk; ask your clinician about safe combinations.
The caffeine component can interact with drugs that affect caffeine metabolism. Fluoroquinolone antibiotics (e.g., ciprofloxacin, enoxacin) may raise caffeine levels, potentially increasing tremor, restlessness, or palpitations. Consider reducing other caffeine sources when taking Cafergot. Sedatives may counteract caffeine’s alerting effects without reducing ergot-related risks—avoid self-adjusting medications and seek professional guidance.
Cafergot is not taken on a fixed schedule. If you do not take it at the onset of an attack, you can still use it as directed during that episode, staying within per-attack and weekly maximums. Do not “make up” for a missed opportunity by exceeding dose limits later in the day or week.
If attacks are frequent enough that you’re tempted to use Cafergot several days per week, talk with your clinician about preventive options and alternative acute therapies to reduce overall exposure and the risk of medication-overuse headache.
Ergotamine overdose can lead to severe vasospasm (ergotism), presenting with intense limb pain, paresthesias, pallor or cyanosis of fingers/toes, diminished pulses, chest pain, abdominal pain, persistent vomiting, confusion, or seizures. This is a medical emergency. Call your local emergency number or poison control right away. Do not take additional vasoconstrictive medications.
Management typically involves supportive care, control of nausea, careful cardiovascular monitoring, and medications to reverse vasospasm where appropriate. If a large ingestion occurred recently, clinicians may consider activated charcoal. Early medical evaluation improves outcomes—bring the medication bottle or a list of doses taken if possible.
Store Cafergot at controlled room temperature (generally 20–25°C/68–77°F), protected from excessive heat, light, and moisture. Keep tablets in a tightly closed container and out of reach of children and pets. Do not use medications past their expiration date, and dispose of them per pharmacy guidance or local take-back programs.
If you carry Cafergot for on-the-go use, avoid leaving it in hot cars or humid bathrooms, which can degrade potency. Check the appearance of tablets periodically and replace if compromised.
In the United States, Cafergot (ergotamine-caffeine) is a prescription-only medication. There is no legal pathway to buy Cafergot without prescription. Any website or vendor offering ergotamine products “no Rx needed” is a red flag for counterfeit, unsafe, or illegally imported drugs. For your safety and to stay compliant with U.S. law, obtain Cafergot only after evaluation by a licensed clinician and fill it through a verified pharmacy.
If you’re seeking convenient access, reputable health systems and telemedicine services can provide a structured clinical assessment and, when appropriate, an electronic prescription to your pharmacy. Large integrated systems (for example, Geisinger and other reputable providers) offer legitimate care pathways—but they do not bypass the requirement for a prescription. Avoid unverified online sellers; look for pharmacies accredited by the National Association of Boards of Pharmacy (e.g., .pharmacy domains) or recognized by LegitScript.
If Cafergot is not right for you or is unavailable, your clinician may recommend alternatives such as triptans, gepants (ubrogepant, rimegepant), ditans (lasmiditan), or NSAIDs, tailored to your medical history. Discuss insurance coverage and generic options to minimize cost. Bottom line: do not attempt to buy Cafergot without prescription—use a legal, clinician-guided process to ensure the medication is safe and appropriate for your migraines.
Cafergot combines ergotamine tartrate and caffeine to treat acute migraine attacks. Ergotamine constricts dilated cranial blood vessels and reduces neurogenic inflammation, while caffeine enhances absorption and adds a mild vasoconstrictive effect.
Cafergot is used for acute treatment of migraine with or without aura. It is not for prevention and not for tension headaches; historically it has been used in select cases of cluster headache under specialist guidance.
Take it at the first sign of migraine pain or aura. A common regimen is 2 tablets at onset, then 1 tablet every 30 minutes as needed; do not exceed 6 tablets for a single attack or 10 tablets in any 7-day period unless your clinician advises differently.
Do not exceed 6 mg ergotamine (6 tablets) in 24 hours and 10 mg (10 tablets) in a week. Using more increases the risk of serious side effects, including ischemia and medication-overuse headache.
Avoid Cafergot if you have coronary artery disease, history of heart attack or stroke, uncontrolled hypertension, peripheral vascular disease, severe liver or kidney impairment, sepsis, or known hypersensitivity to ergot alkaloids. It is contraindicated in pregnancy and breastfeeding, and in hemiplegic or basilar/brainstem migraine.
Nausea, vomiting, dizziness, flushing, abdominal discomfort, muscle cramps, and tingling in fingers or toes are common. Caffeine can cause jitteriness or palpitations in sensitive individuals.
Seek immediate help for chest pain, shortness of breath, severe or worsening headache, confusion, vision or speech changes, fainting, cold or numb extremities, severe limb pain, or bluish fingers or toes, which may signal vasospasm or ischemia.
Yes. Using ergotamine products more than 10 days per month can trigger rebound headaches. Keep usage within recommended limits and discuss a preventive plan if attacks are frequent.
Do not combine with triptans or other ergot drugs within 24 hours. Avoid strong CYP3A4 inhibitors (such as erythromycin, clarithromycin, ritonavir, ketoconazole), certain antifungals, some HIV medications, and grapefruit, which can raise ergotamine levels and cause dangerous vasospasm. Use caution with beta-blockers and nicotine due to additive vasoconstriction.
No. Ergotamine can cause uterine contractions and reduce placental and breast blood flow; it is contraindicated in pregnancy and while breastfeeding.
It can still help, but it’s most effective when taken early. If nausea or vomiting limits absorption, ask about using an antiemetic or alternative acute options.
Cafergot can be used for migraine with typical aura, but it should not be used for hemiplegic migraine or basilar/brainstem aura. Discuss your specific aura symptoms with your clinician.
Dizziness and drowsiness can occur. Until you know how you respond, avoid driving or hazardous tasks.
Availability varies by country and over time; some regions have limited or discontinued brands while others carry ergotamine/caffeine generics. Your pharmacist can advise on local options.
Store at room temperature away from moisture and heat, in its original container, and keep out of reach of children. Do not use past the expiration date.
If vomiting occurs soon after dosing, absorption may be incomplete. Contact your clinician for individualized advice; you may be advised on antiemetics, alternative formulations, or whether a repeat dose is appropriate within the maximum limits.
It should not be used with uncontrolled hypertension due to vasoconstriction risk. If your blood pressure is controlled, your clinician will assess risks versus benefits.
Some people feel relief within 30 to 60 minutes, especially when taken early in the attack. Full benefit may require additional doses within the prescribed limits.
No. It is only for acute attacks. Overuse increases risks; explore preventive medications if you have frequent migraines.
Both treat acute migraine by narrowing cranial blood vessels, but triptans more selectively target serotonin receptors and are generally better tolerated. Cafergot may be an option when triptans are ineffective or contraindicated, but it has more vascular cautions and drug interactions.
DHE (injection or nasal) is another ergot derivative with a somewhat broader therapeutic window and often fewer ischemic complications than ergotamine. Choice depends on attack pattern, nausea severity, access to routes (nasal, IV), and cardiovascular risk; many specialists prefer DHE in refractory cases.
Rizatriptan orally disintegrating tablets often act within 30 minutes and are generally more predictable. Cafergot can work quickly if taken at onset, but variability in absorption and side effects can limit speed and consistency.
Neither is appropriate for established coronary artery disease or uncontrolled hypertension due to vasoconstriction. Non-vasoconstrictive options like gepants (ubrogepant, rimegepant) or lasmiditan are often preferred for patients with cardiovascular disease.
NSAIDs (ibuprofen, naproxen) are first-line for many mild to moderate attacks with a favorable safety profile. Cafergot may be considered for moderate to severe attacks that don’t respond to NSAIDs, but carries more contraindications and interaction risks.
Gepants block CGRP without vasoconstriction, making them suitable for patients with vascular risk and for use on multiple days per month. Cafergot can be effective but has stricter limits, more interactions, and a higher risk of vascular side effects.
Lasmiditan is a 5-HT1F agonist with no vasoconstriction, safer for many cardiovascular patients, but causes central side effects like dizziness and requires an 8-hour driving restriction. Cafergot constricts vessels and has vascular contraindications but doesn’t impose a driving restriction per label; its side effect profile is more peripheral and gastrointestinal.
Head-to-head data generally favor triptans for efficacy and tolerability. Some individuals respond better to ergotamine, but population-level response and consistency tend to be higher with triptans.
Yes. Caffeine enhances ergotamine absorption and adds mild vasoconstriction, improving onset and efficacy for some patients compared with ergotamine alone.
Zolmitriptan nasal bypasses the gut and may act quickly, which helps when nausea or vomiting is present. Cafergot tablets may be less reliable in that scenario; if ergot therapy is desired, DHE nasal or injection may be preferable.
For many, an NSAID plus metoclopramide or prochlorperazine provides robust relief with fewer vascular risks. Cafergot can be reserved for cases not controlled by such regimens or when triptans are unsuitable.
Both can cause MOH, but ergotamine has a particularly strong association when overused. Strict adherence to monthly limits is crucial with either drug.
They serve different roles: Cafergot treats attacks; CGRP mAbs prevent them. Many patients on preventives still need an acute option, which may be a triptan, gepant, ditan, NSAID, or Cafergot depending on individual factors.
Ergotamine/caffeine can be inexpensive where available. Newer agents often cost more but may offer better tolerability, fewer interactions, and suitability in cardiovascular disease, which can justify their use despite higher price.